Chapter from the book *Coronary Artery Diseases*
Downloaded from: http://www.intechopen.com/books/coronary-artery-diseases

Interested in publishing with IntechOpen?
Contact us at book.department@intechopen.com
1. Introduction

1.1 Cardiovascular diseases and Percutaneous Coronary Intervention (PCI)

Coronary Artery Disease (CAD) is the chronic blocking or narrowing of the coronary arteries caused by neointimal hyperplasia of the arterial wall. It has been the number one killer in the United States since 1900 and remains a common cause of death in the Western world despite therapeutic advances. Approximately 14 million Americans have CAD, 500,000 people die from acute myocardial infarction, and one million more survive but with a 1.5 to 15 times greater risk of mortality or morbidity than the rest of the population each year. The annual health care cost of the disease is in excess of $112 billion. The current levels of predictors of heart disease risk, such as obesity, diabetes, and smoking, suggests that this will continue to be a significant public health problem for the foreseeable future.

The options for CAD treatments include medications, percutaneous coronary arterial interventions (PCI, including angioplasty and stenting), or coronary artery bypass graft surgery (CABG). In general, patients with coronary narrowing that does not limit coronary artery blood flow receive medications and lifestyle modification to help prevent progression. If a patient has coronary atherosclerosis that limits blood flow in the coronary arteries, balloon angioplasty and stenting can be offered. In patients with multiple areas of coronary artery narrowing or blockage, CABG is generally recommended.

1.1.1 Coronary Artery Bypass Graft Surgery (CABG)

Of those patients with coronary artery disease, about 10% undergo CABG surgery. Patients with severe narrowing or blockage of the left main coronary artery or those with disease involving two or three coronary arteries are generally considered for bypass surgery. In a CABG, the surgeon uses a portion of a healthy vessel (either an artery or vein) from the leg, chest, or arm to create a detour or bypass around the blocked portion of the coronary artery. Depending on how many coronary arteries (and main branches) are blocked, patients typically receive 1 to 5 bypasses. The most commonly used bypass vessels are the saphenous vein from the leg, the internal mammary artery from the chest,
and the radial artery from the arm. During a CABG, a heart-lung machine artificially maintains circulation while the surgeon operates on the heart. CABG operations require general anesthesia and typically 4 to 7 days in the hospital. It may take up to 3 months to fully recover from the surgery.

1.1.2 Percutaneous Interventions (PCIs)

Percutaneous Interventions (PCIs), which include percutaneous transluminal coronary artery angioplasty (PTCA) and coronary artery stenting (CAS) are the major therapies for CAD treatment. PTCA involves insertion of an expandable balloon catheter against a primary atherosclerotic plaque or secondary restenotic lesion to increase vessel patency and blood flow. Clinical stenting was introduced in 1986 with the Wallstent to repair abrupt closure after PTCA and has revolutionized interventional cardiology. In CAS, the stent (a tiny metal scaffolding) functions to brace the vessel wall and reduce the risk of restenosis following angioplasty. CAS reduces the rate of angiographic and clinical restenosis compared to PTCA alone. This results in a significant reduction in the frequency of major adverse cardiac events (MACE) after PCI driven mainly by a reduction in target vessel revascularization (TVR). CAS not only increases procedural success rates, but also increases the safety of procedures by decreasing the need for emergency CABG surgery. As a result, stents are currently utilized in over 85% of the two million PCIs in US and the total direct cost for those life-saving procedures is over $5 billion annually.

1.2 Problems in current DESs

Since the introduction of the stent, there exist two serious complications: namely, thrombosis (subacute and late-stage) and in-stent restenosis (ISR). While subacute thrombosis has been controlled with the use of dual anti-platelet therapy, late-stage thrombosis occurring in drug-eluting stents (DESs) has been a big concern recently. Restenosis remains among the most challenging problems in interventional cardiology. The recent development of DESs is a major breakthrough as a potential solution for the restenosis problem.

1.2.1 In-stent Restenosis (ISR)

Restenosis, the re-narrowing of an opened artery after stenting or PTCA procedure, is due to a proliferative response of the intima, a layer of cells that lines the lumen of the vessel composed of connective tissue and smooth muscle cells (SMC). In restenosis, vascular neointimal hyperplasia results in complete blockage of the original artery and insufficient oxygenation of cardiac tissue, leading to cardiac arrhythmia or cardiac arrest. Restenosis has been the biggest problem in PCI until the recent successful development of DESs. Initially, the restenosis rate in PTCA procedures was over 50% within six months post balloon dilation. Stenting lowers this rate to 20-30%. Both Sirolimus (Cypher®, Cordis Inc, Fla) and Paclitaxel (Taxus®, Boston Scientific Inc, Natick, MA) coated DESs can significantly reduce the rate of restenosis to <10%.4-6 However, restenosis in patients with high risk such as small vessels, diabetes, and long diffusion diseased arteries still remains
ISR formation is a multi-factorial, sequential process. Although the detailed mechanism of the arterial tissue response to an implanted stent is still under investigation, it is generally believed that three stages are involved in the process. 1) Thrombotic Phase (day 0-3): this phase is the initial response of the artery tissue to stent implantation characterized with rapid activation, adhesion, aggregation and deposition of platelets and neutrophils to form a thrombus at the injured site. 2) Recruitment Phase: this phase occurs between days 3 to 8 and is characterized by an intensive inflammatory cell infiltration. In this phase, inflammatory cells are activated and infiltrate into the injured vessel wall. Subsequently, the recruited inflammation cells provide the key stimulus for subsequent smooth muscle cell (SMC) proliferation and migration. 3) Proliferate Phase: This phase lasts 1 to 3 months depending on the thickness of the residual thrombus and the rate of growth. At this stage, inflammation cells colonize the residual thrombus, forming a “cap” across the mural thrombus. The cells progressively proliferate, resorbing residual thrombus until all thrombus is gone and is replaced by the neointima tissue.

The process of neointimal growth, which consists of SMCs, extracellular matrix, and macrophages recruited over a period of several weeks, is similar to the process of tumor tissue growth. This pathologic similarity between tumor cell growth and benign neointimal formation has led to the discovery of anti-tumor drugs such as Paclitaxel as effective agents for the treatment of ISR.

1.2.2 Stent thrombosis

In spite of restenosis remaining a clinical problem in approximately 10% of patients with DES implantation, it can often be successfully treated with repeat implantation. The greatest concern, however, has been for stent thrombosis which is associated with a high rate of myocardial infarction and death. The rate of early stent thrombosis (less than 30 days following implantation) appears similar in both BMSs and DESs (Cypher® and Taxus®). However, late stent thrombosis has been increasingly reported beyond 12 months following DES implantation with the greatest risk occurring as a result of premature discontinuation of anti-platelet therapy. Although the precise mechanism of late stage stent thrombosis is unknown, it is generally believed that the combination of delayed endothelialization due to anti-proliferative therapy and persistence of the nonerodable polymer contribute to a hypersensitivity reaction, possibly with some residual active drug that may not be eluted.

2. The structure and components of a drug eluting stent

Drug eluting stents are comprised of three major parts: 1) drug delivery platform (metal stent) to hold the drug and provide supporting forces for the collapsed artery; 2) drug coating polymer to attach the drug on the stent surface; 3) anti-restenosis drugs released from the stent to inhibit restenosis formation after stent implantation. We review each component systemically in order to have an anatomic understanding of drug eluting stent.
2.1 Stent platforms

2.1.1 Stent materials

2.1.1.1 Non degradable material

316L stainless steel: 316L stainless steel (316L SS) is the most commonly used metal material in stents due to its excellent mechanical properties and corrosion resistance and is used in the first generation DESs, Cypher (sirolimus-eluting stent, Cordis, Warren, NJ) and Taxus (paclitaxel-eluting stent, Boston Scientific, Natick, MA). However, its ferromagnetic nature and low density make it a non-MRI compatible and poorly visible fluoroscopic material. Furthermore, the release of nickel, chromate and molybdenum ions is likely to provoke immune reactions and inflammatory responses, which may result in ISR\textsuperscript{22}. Therefore, a number of materials have been used as coatings to improve its visibility and biocompatibility.

Co-Cr: Co-Cr alloy exhibits superior radial strength and improved radiopacity compared to 316L SS. It allows for thinner stent struts, which is a significant advantage because the thickness of stent struts is a important factor on the reduction of restenosis in BMS\textsuperscript{23, 24}. At the same time, it reduces device profile and consequently improves its deliverability to the target lesion. Co-Cr platforms are employed in the second generation DES, Xience V (everolimus-eluting stent, Abott Vascular, CA) and Endeavor (zotarolimus-eluting stent, Medtronic Vascular, Santa Rosa, CA).

Ta: The highly stable surface oxide layer, preventing electron exchange between the metal and the absorbed biological species\textsuperscript{25, 26}, make Ta an excellent corrosion resistant material. Ta has been coated on 316L SS to improve corrosion properties and biocompatibility of 316L SS\textsuperscript{27}. Its high density and non-ferromagnetic properties\textsuperscript{28, 29} make Ta an excellent fluoroscopically visible and MRI compatible material. However, its poor mechanical properties make Ta stents have higher rates of recoil compared to 316L SS based stents and result in enhanced neointimal formation\textsuperscript{30}. Although no Ta based stents have been approved by FDA for general use to date, a bare Ta stent has been used by Cordis® (Johnson & Johnson, USA) in clinical trials and released commercially in Japan, Canada and Europe\textsuperscript{31}.

Ti: Although Ti has excellent biocompatibility and corrosion resistance, pure Ti is not commonly used for making stents due to its low tensile strength and ductility. However, Ti alloys might be optimum for stents. Ti-nitride-oxide coating on 316L SS was biologically inert, reducing platelet and fibrinogen deposition, and neointimal hyperplasia\textsuperscript{32}. Promising results were reported in clinical trials by the Titan stent (Hexacath, France) using this coating\textsuperscript{33, 34}. Moreover, Ti-based Ta and niobium alloys showed excellent haemocompatibility\textsuperscript{35}, indicating they have potential applications for stents. An extensively used Ti alloys in stents is Ni-Ti.

Ni-Ti: Ni-Ti alloy is also a common material for stents which has good biocompatibility, radial force and shape memory. However, the release of nickel ions and their toxic effects on tissues have been reported\textsuperscript{36, 37}. In addition, it is suspected of producing mild inflammation when contacting monocytes\textsuperscript{38}. In order to solve these problems, the surface of Ni-Ti is passivated to increase the Ti oxide concentration and decrease the Ni concentration\textsuperscript{39, 40}, and it is coated by some materials such as polyurethane\textsuperscript{41}, Ti nitride\textsuperscript{42} and polycrystalline oxides\textsuperscript{43} to improve the corrosion resistance. Another problem is that the Ni-Ti alloy does
not have adequate visibility under fluoroscopy though it can be visualized by MRI. Ni-Ti is used by ACT-One® (Progressive Angioplasty Systems, USA), Paragon (Progressive Angioplasty Systems, USA), and Radius (Scimed, USA) in clinical trials.

**Pt-Ir**: The bare stents made from Pt-Ir alloy of 90% platinum and 10% iridium have been implanted in animal models, showing excellent radiopacity and a reduction in both thrombosis and neointimal proliferation with less inflammatory reactions. However, their recoiling percentage was much higher (16%) than the 316L SS stents (5%). Though Pt-Ir alloy stents have been proved safe and effective in a human clinical trial, the biocompatibility and haemocompatibility of Pt-Ir alloys needs be further investigated.

### 2.1.1.2 Biodegradable metallic materials

Besides the aforementioned non-degradable metallic stents, a new concept is biodegradable metallic stent. The recently used biodegradable metallic materials are pure Fe and Mg alloys.

**Pure Fe**: The degradation of Fe was completed through the oxidation of Fe into ferrous and ferric irons which were dissolved into biological media. It is reported that ferrous ions could reduce the proliferation rate of vascular smooth muscle cell *in vitro* by influencing growth-related gene expression and therefore may antagonize restenosis *in vivo*. The pure Fe (more than 99.5%) stents with strut thickness varied from 100 to 120µm have been implanted successfully in rabbit and porcine and endothelialization was observed. However, further investigation is needed on the modification of the composition and design of the stent to expedite the degradation process.

**Mg alloys**: Mg and its alloys has been used as orthopedic materials, but it is a new principle to apply these materials to coronary stents. Unlike pure Fe, pure Mg is not suitable for making stents due to mechanical and corrosion properties. There are two Mg alloys, AE21 and WE43, used for making stents. These materials are radiolucent and thus cannot be imaged by X-rays. However, they can be visualized by intravascular ultrasound and MRI. The Lekton Magic stent (Biotronik, Switzerland) is made from WE43, which is safe and can provide sufficient support to the collapsed arteries within its degradation time (2-3 months). It has been implanted in porcine models, and the preliminary clinical data showed promising results that after one-month implantation of magic stents, 18 out of 20 patients had normal flow while 30%-40% restenosis occurred in the other 2 patients. However, mixed results were found in a human study using a Biotronik’s Mg absorbable metal stents, indicating further evaluation is needed.

### 2.1.2 Stent geometric design

**Self-expanding vs. balloon-expandable**: Basically, there are two stent types: the self-expanding and the balloon-expandable stents. The self-expanding stent is made of a coil, mesh or zigzag configuration that is constrained with an outer sheath. The stent elastically springs open to a predetermine size after the sheath is removed. The balloon-expandable stent is crimped and premounted on a balloon, and expanded by the inflation of the balloon whose diameter determines the size of expanded stent. Though the self-expanding stent will expand to a calculated size automatically, it is not recommended and seldom used at present because it continues to expand in the weeks after deployment and thus leads to the...
stent migration to the adventia and the stent cross-sectional area increasing accompanied by medial compression\textsuperscript{63, 64}.

**Coil vs. Tube:** Generally, the balloon-expandable stent is classified into two groups: the tube and the coil design. The tubular stent is cut from a steel tube or a flat sheet of metal which is then rolled and welded to form a tube. The coil design is composed of a continuously wound wire or a series of flat sheet coils, which has a greater strut width with gaps and fewer or no connections between struts compared with the tubular stent\textsuperscript{65}. These characteristics make coil stents more flexible but have poor radial strength and the wide gap allows tissue prolapse\textsuperscript{66}. As a result, coil design is being replaced by the tube design gradually.

**Slotted tube vs. Modular:** Tubular balloon-expandable stents also can be divided into two types: slotted tube and modular design. Both of them are cut from a tube of metal. A clinical study showed slotted tube stents resisted restenosis more than the modular stents (22.1\% vs 25.2\%\textsuperscript{67}). The slotted tube stent also has two kinds: one is closed cell design, and the other one is open cell design. The former one is loser to the original concept of slotted tubes, while the latter is more like the modular stent. In a clinical study, less platelet activation was found in the implantation of closed cell stents than the open cell stents, which may have resulted from a greater degree of tissue prolapsed with the open cell stents\textsuperscript{68}.

**Long vs. Short:** It has been proven that stent length is associated with restenosis rate and clinical events (mainly target lesion revascularization): 20 mm length stent resulted in 22.6\% angiographic restenosis rate; 27 mm length stent led to 36\% angiographic restenosis rate; and 43 mm length stent produced 67.5\% angiographic restenosis rate\textsuperscript{69}. Similar results were found in another clinical study that showed the angiographic restenosis rates were 20.8\% and 37.3\%, respectively, in the implantation of 16 mm and \( \geq 32 \) mm BMSs, and the angiographic restenosis rates were 7.2\% and 10.3\% for the implantation of the same length of DESs\textsuperscript{70}. Therefore, stent length is still a problem in DESs. On the one hand, the DESs can reduce restenosis in both long and short lesions compared with BMSs, but a long stent is expected to cover all the diseased area. On the other hand, a long DES may increase the occurrence of restenosis.

**Wide vs. Narrow:** As with stent length, the stent width is another problem in both BMSs and DESs. The same study mentioned above showed the angiographic rates were 40.8\% in the 2.5 mm diameter vs. 12.9\% in the 3.5 mm diameter BMSs, and 8.8\% vs. 5.5\% in the same diameter DESs\textsuperscript{70}. Although the study suggested that the wide diameter stent is more favorable than the narrow one, the width is still a problem which has not been eliminated by DESs.

**More struts vs. less:** An animal study, of stainless steel stents with different configurations implanted in rabbit iliac arteries, indicated that the stents with 12 struts per cross section had 50\% to 60\% less mural thrombus and 2-fold less neointimal area than those of identical stents with only 8 struts per cross section\textsuperscript{71}. However, another animal study showed the neointimal growth is not related to the number of struts, but associated with the stretching of arteries and the injury depth caused by the implantation of stents\textsuperscript{72}. Therefore, further research is needed to evaluate the impact of the number of struts in a stent on thrombosis and restenosis.
**Thick vs. thin struts:** As discussed above, the injury depth and the stretching of the coronary arteries have a great impact upon neointimal growth\(^2\), and the two parameters are vary inversely with the thickness of the stent struts. Thinner struts slice into tissue more easily and hence induce more deep injury to the coronary arteries, but unlike thicker struts, they cause less angulations and stretching of the arterial wall. The effect of strut thickness on restenosis incidence was evaluated in both ISAR-STEREO and ISAR-STEREO 2 trials\(^{23, 24}\). In the ISAR-STEREO trial, 326 patients were implanted with thin-strut stents (strut thickness is 50 µm) while in the other 325 patients were assigned to receive thick-strut stents (strut thickness is 140 µm) randomly. The results showed the incidence of angiographic restenosis was 15.0% in the thin-strut group vs. 25.8% in the thick-strut group \((P=0.003)\), clinical restenosis was also significantly reduced, with a reintervention rate of 8.6% among thin-strut patients vs 13.8% among thick-strut patients (relative risk, 0.62; 95% CI, 0.39 to 0.99; \(P=0.03\)), and no difference was observed in the combined 1-year rate of death and myocardial infarction (MI)\(^{23}\). In the ISAR-STEREO 2 trial, a total of 611 patients with symptomatic coronary artery disease were randomly assigned to receive two different kind of stents in both design and strut thickness: the thin-strut ACS RX Multilink stent with interconnected ring design (Guidant, Advanced Cardiovascular Systems, Santa Clara, California) (strut thickness 50 µm) were implanted into 309 patients while the thick-strut BX Velocity stent with closed cell design ( Cordis Corp., Miami, Florida) (strut thickness 140 µm) were implanted into 302 patients. The results showed the incidence of angiographic restenosis was 17.9% in the thin-strut group vs. 31.4% in the thick-strut group \((p < 0.001)\), a target-vessel revascularization (TVR) due to restenosis was required in 12.3% of the thin-strut group vs. 21.9% of the thick-strut group \((p = 0.002)\), and no significant difference was observed in the combined incidence of death and MI at one year\(^{24}\). Therefore, the stents with thinner struts is preferred for the design of new stents as they can reduce angiographic and clinical restenosis more than those with thicker struts.

**Square vs. round strut cross-section:** Another note worthy stent geometry is the shape of the strut cross-section. An in vitro study showed the migration distance of human aortic endothelial cells along the surface of the flat pieces of 316L stainless steel with the sharpest edge angles of the bottom surfaces \(35^\circ\) was significantly greater than with larger angles \(70^\circ, 90^\circ, \text{ and } 140^\circ\) \((P < 0.05)\) under static and flow conditions, indicating the edge angle of stent struts does influence the rate of endothelialization. The stents with smaller edge angles and slopes facilitate endothelialization as compared with the larger angles\(^{73}\). In addition, when compared to those with smaller edge angles, the stents with larger angels have sharper edges in the direction of blood flow, which may interfere with blood by slicing the blood cells. Therefore, the square strut cross-section is not recommended and the round strut cross-section without corners or sharp edges is popular at present.

**Rough vs. smooth surface:** The stent surface topography is thought to play an important role in stent performance. Though some studies showed a smooth, polished surface reduced thrombus adhesion and neointimal growth\(^{74}\), it does not mean extremely smooth surfaces are optimal for re-endothelialization. Recently, an in vitro study suggested that a stent surface with a microscopic pattern of parallel grooves disposed in the direction of blood flow leads to a faster re-endothelialization process than the stent with smooth surface\(^{75}\). In addition, in a recent animal study, a similar result was observed a stent with a microscopic parallel grooves accelerated the endothelialization rate significantly 1 week after implantation in porcine carotid arteries compared to smooth stents\(^{76, 77}\). In order to
determine the relationship between the stent surface topography and outcome in patients undergoing implantation of stents with rough and smooth surfaces, a clinical trial of 200 patients with significant stenosis in native coronary vessels were randomly assigned in a double-blind study to receive either a rough or a smooth-surface stent. The study indicated rough stent surface does not increase late lumen loss after stent implantation as compared with a conventional smooth stent surface, and the angiographic restenosis rates were 25% with rough-surface stents vs 35% with smooth surface stents (P=0.19)\textsuperscript{78}. Therefore, a relatively rough surface is better for stent performance than a smooth one.

**Symmetry of Deployment:** Previous studies suggested that the degree of restenosis is related to the symmetry of stent expansion and increased neointimal thickening was found in the unevenly deployed stents\textsuperscript{71, 79}. In the presence of calcified lesions, the stents usually were expanded asymmetrically\textsuperscript{80, 81}. It is believed that the symmetry of stent deployment might be influenced by the balloon folding patterns\textsuperscript{82}. Currently, trefoil or tetafoil folding is common, which prevents excessive expansion of one side of the stent\textsuperscript{83}.

### 2.2 Drug delivery vehicles – Coating polymer

Polymers are large molecule compounds consisting of repeating structural units typically connected by covalent chemical bonds, which can be broadly classified into nonbiodegradable and biodegradable polymers when used as drug carriers in DESs.

#### 2.2.1 Non biodegradable polymers

Both the first and the second generation of DESs are using nonbiodegradable polymers to control the drug-elution profile. In the first generation of DES, Cypher (sirolimus-eluting stent, Cordis, Warren, NJ) used polyethylene-co-vinyl acetate (PEVA)/poly-n-butyl methacrylate (PBMA) to delivery sirolimus, while Taxus (paclitaxel-eluting stent, Boston Scientific, Natick, MA) used polystyrene-b-isobutylene-b-styrene (SIBS) to delivery paclitaxel. Both stents can reduce restenosis significantly compared to BMSs\textsuperscript{70,84-86}, however, an increase in the rate of MI and mortality was reported in patients following 18 months to 3 years after the implantation of Cypher or Taxus\textsuperscript{87-90}. In the second generation of DES, Xience V (everolimus-eluting stent, Abott Vascular, CA) employed a fluoropolymer to carry everolimus, while Endeavor (zotarolimus-eluting stent, Medtronic Vascular, Santa Rosa, CA) employed phosphorylcholine (PC) to carry zotarolimus. Compared with the respective BMS, the target vessel revascularization (TVR) was reduced significantly by both Endeavor and Xience V stents\textsuperscript{91,92}. Xience V stents reduced angiographic late loss without an increase of stent thrombosis compared with Taxus stents in the SPIRIT III study\textsuperscript{93}, whereas Endeavor stents showed a higher incidence of restenosis compared with Cypher stents in the ENDEAVOR III trial\textsuperscript{94}. However, both Endeavor and Taxus stents had an equivalent target lesion revascularization rate in a later trial\textsuperscript{95}. In addition, there were no cases of very late stent thrombosis in earlier ENDEAVOR trials over 4 years indicating Endeavor stents are safe in the long-term\textsuperscript{96}.

#### 2.2.2 Biodegradable polymers

As nonbiodegradable polymers may lead to inflammatory response\textsuperscript{97}, the biodegradable polymers applied for stent coatings to delivery drugs are being investigated. The most
commonly used polymers now are polylactic acid (PLA), polyglycolic acid (PGA) and their copolymer, polylactic-co-glycolic acid (PLGA)\textsuperscript{98, 99}, which are fully metabolized to water and carbon dioxide and excreted via the respiratory system. Despite a series of promising preliminary data that was reported\textsuperscript{100-103}, the development of biodegradable polymers in DES is still challenging. On the one hand, the degradation of polymers are affected by a variety of factors\textsuperscript{104} such as the pH, the polymer’s size, molecular weight and crystallinity, etc, making the drug release control difficult. On the other hand, the accumulated acidic products from polymer degradation may result in significant inflammatory response of the vessel wall and therefore lead to restenosis.

2.2.3 Other materials and methods

Other stents that do not use a polymer at all are still under development. For example, a titanium–nitric oxide alloy has been applied to stainless steel stents with encouraging results, including decreased platelet adhesion and neointimal hyperplasia compared with BMS\textsuperscript{34}. A microporous stainless steel stent (Yukon, Translumina, Germany) allows for dose-adjustable, multiple drugs, and on-site coating\textsuperscript{105} [63]. The system is therapeutically effective with rapamycin\textsuperscript{106}. A nanoporous hydroxyapatite (a biocompatible crystalline derivative of calcium phosphate) coating, which can be impregnated with anti-restenotic drugs, is currently under development\textsuperscript{107}. A stainless steel stent coated with nanoporous aluminium oxide and tacrolimus showed disappointing results, however, with evidence of particle debris shed from the coating contributing to increased neointimal hyperplasia\textsuperscript{108}. An interesting drug delivery system developed recently is composed of magnetic nanoparticles (MNPs) loaded with endothelial cells and a 304 grade stainless steel\textsuperscript{109}. The endothelial cells were loaded on polylactide modified MNPs and then moved by a magnetic field gradient towards the stent surface after injection, which enabled artificial endothelialization and repeated dosing, showing promising future. However, further evaluation in animal studies and clinical trials is required.

2.3 Therapeutic agents

2.3.1 Sirolimus and its analogues

\textit{Sirolimus}: Sirolimus (rapamycin), a macrocyclic lactone used in the Cypher stents, binds to FK-binding protein 12 and subsequently inhibits the mammalian target of rapamycin (mTOR). The mTOR prevents the degradation of p27kip1, a cyclin-dependgent kinase inhibitor, thereby inhibits the migration and proliferation of SMCs\textsuperscript{110, 111}. However, the mTOR is also a downstream target of the phosphatidylinositol-3 kinase pathway, which inhibits the tissue factor in endothelial cells and monocytes\textsuperscript{112-114}, Therefore, the inhibition of mTOR by sirolimus leads to increasing expression and activity of tissue factor in endothelial cells\textsuperscript{112}.

\textit{Zotarolimus}: The former name of zotarolimus is ABT-578, which is one of the sirolimus analogues developed by Abbott laboratories. The extremely lipophilic property and low water solubility\textsuperscript{115} make zotarolimus a better candidate for DES than sirolimus. It has been employed in Medtronic’s Endeavor stents which was approved by FDA in 2008 and showed better endothelialization than Cypher at 14 days post implantation\textsuperscript{116}. It is also used in Zomaxx stents developed by Abbott laboratories\textsuperscript{117}. 

www.intechopen.com
Everolimus: Everolimus is another sirolimus analogue, which is also used as an immunosuppressive agent. As with sirolimus, it inhibits smooth muscle cell proliferation and in-stent neointimal growth. However, compared to sirolimus, everolimus has a better pharmacokinetic profile and bioavailability when used in organ transplant. When it is used in intracoronary elution, everolimus absorbs to local tissue more rapidly and has a longer cellular residence time and activity. It has been used in another FDA approved stent, Xience V, which also showed better endothelialization than Cypher at 14 days post implantation of stents.

Biolimus A9: Biolimus A9 has similar immunosuppressive potency to sirolimus, but it is absorbed by vessel walls more readily and enters cells more rapidly. It has been investigated in two PLA coated stainless steel stents, Biomatrix (Biosensors International, Singapore) and Nobori (Terumo, Japan). The biolimus-eluting stent has been proven to be safe and effective in reducing neointimal proliferation when compared to BMSs and Taxus in the Nobori 1 trial.

2.3.2 Paclitaxel and its analogues

Paclitaxel: Paclitaxel, a lipophilic diterpenoid, binds to β-subunit of the tubulin heterodimer, promoting tubulin polymerization and cell cycle arrest, thus inhibiting the migration and proliferation of SMCs. Notwithstanding, an important regulator of endothelial and monocytic tissue factor induction, c-Jun NH2-terminal kinase, is also activated by paclitaxel, and, consequently, enhances the activity of tissue factor in endothelial cells.

Coroxane: To improve the solubility of paclitaxel and reduce non-drug-related toxicities, a protein-engineered nanoparticle albumin bound paclitaxel (nab-paclitaxel) named Coroxane was developed by Abraxis Bioscience Inc.. The phase I study has been conducted showing 10-30 mg/m² doses of the drug are safe for humans. The phase II study is ongoing.

Docetaxel: Docetaxel is a semi-synthetic analogue of paclitaxel used for the treatment of ovarian, breast and non-small cell lung cancer. Compared to paclitaxel, docetaxel has better anti-proliferative properties, however, it has dose-dependent cytotoxicity.

2.3.3 Others

Tacrolimus: Tacrolimus (FK-506 or Fujimycin or Prograf), a hydrophobic macrolide immunosuppressant drug, is a T cell inhibitor resulting in cell apoptosis by holding cells in the G0 phase of the cell cycle and has a different mechanism from that of sirolimus. Moreover, unlike the mTOR inhibitors and paclitaxel, tacrolimus does not increase expression of tissue factor since it has a preferential effect on SMCs as suppressed endothelial cells. Although some studies showed that tacrolimus-eluting stents can significantly reduce neointimal proliferation, a study on Janus, a new design of tacrolimus-eluting stent (Sorin Biomedica Cardio, Italy), indicated the performance of Janus was no better than a BMS. Other tacrolimus-eluting stents and their long term outcomes are still under investigation.

Pimecrolimus: Pimecrolimus (SDZ ASM 981), an analogue of ascomycin, has similar effects and mechanism of tacrolimus. It has received substantial interest for its significant anti-inflammatory activity, immunomodulatory capabilities and low systemic immunosuppressive potential.
Curcumin: Curcumin, a component of turmeric, exhibits a variety of biological activities such as anti-proliferative activity, anti-inflammatory, anti-oxidant activity, wound healing ability, and anti-microbial activity\textsuperscript{144-146}. Thus, curcumin is an excellent candidate in the application of coronary stents to inhibit the proliferation of SMCs and prevent inflammatory response, and hence prevent the occurrence of restenosis.

Resveratrol: Resveratrol (3, 5, 4'- trihydroxystilbene), is a phytoalexin found in various plants, such as grapes, berries, peanuts and wines, and has many biological activities including anti-fungal, anti-bacterial, anti-viral, anti-oxidant, and anti-inflammatory activity\textsuperscript{147, 148}. It is most important, however, that resveratrol has the potential to be used as a therapeutic agent in DES to inhibit thrombosis and restenosis because of its ability to block the aggregation of human platelets and prevent the proliferation of vascular smooth muscle cells\textsuperscript{149-152}. 

CD 34 antibody: Contrary to SMC inhibition, a novel prohealing technology is used in the Genous\textsuperscript{TM} stent (Orbus Neich, Fort Lauderdale, Florida), which is a stainless steel stent coated with murine monoclonal antihuman CD34 antibodies that attracts endothelial progenitor cell to enhance re-endothelialization. The reported results indicate that the Genous\textsuperscript{TM} stent is effective and promising\textsuperscript{153-156}.

Anti-VEGF: Another similar concept is the bevacizumab-eluting stent (Biocompatibles Ltd., London, UK)\textsuperscript{157}. Bevacizumab, a specific antibody of vascular endothelial growth factor (VEGF), was coated on the surface of BiodivYsio stent to inhibit the development of the vaso vasmorum and thereby promote atheromatous plaque stability. Further investigation is in progress.

Drug Combinations: Besides developing new individual drugs to inhibit thrombosis and restenosis, combining the known effective drugs together on the stents is a novel method. For example, pimecrolimus and paclitaxel were loaded together on Symbio stents; heparin and sirolimus were coated on Synchronnium stents; genistein were combined with sirolimus\textsuperscript{158}.

3. Current commercially available and investigational DESs

Currently, four drug-eluting stents have been approved by the FDA for the U.S. market including: Sirolimus coated Cypher\textsuperscript{®} stent (Cordis, Inc.), Paclitaxel coated Taxus\textsuperscript{®} stent (Boston Scientific, Inc.), Zotarolimus coated Endeavour\textsuperscript{®} stent(Medtronic, Minneapolis, MN) and Everolimus coated Xience\textsuperscript{®} Stent (Abbott, Redwood city, California). Cook, MIV Therapeutics, Inc. and a few others including MicroMedical Group, Inc. have been working hard to enter the stent market as well. The table below provides a summary of currently available and investigational DESs and their status.

Among currently available nonbiodegradable DESs, both Cypher\textsuperscript{®} and Taxus\textsuperscript{®} stents have been well- accepted by clinical cardiologists and patients. The incidences of in-stent restenosis in both stents are effectively confined to less than 10%. However, the common problem faced with both stents is late-stage thrombosis which occurs at approximately 0.4% after one year of implantation. Endeavour\textsuperscript{®} and Xience\textsuperscript{®} are relatively new to the market, and therefore their long-term clinical safety and efficacy need to be further investigated.

Cypher\textsuperscript{®} and Taxus\textsuperscript{®} stents, the first generation of DESs, are constructed from 316L stainless steel, while recently approved Endeavour\textsuperscript{®} and Xience\textsuperscript{®} stents are made from
Cobalt chrome. All four approved DESs are coated with nonbiodegradable polymers. Nonbiodegradable polymers were used rather than biodegradable polymers primarily due to the bio-incompatibility issues of existing biodegradable polymers.

<table>
<thead>
<tr>
<th>Generations</th>
<th>Brand Name</th>
<th>Drugs</th>
<th>Platforms</th>
<th>Strut thickness</th>
<th>Materials</th>
<th>Polymers</th>
<th>Manufacturers</th>
<th>Current Status</th>
<th>FDA</th>
<th>CE Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>First</td>
<td>Taxus®</td>
<td>Paclitaxel</td>
<td>Nir®</td>
<td>132</td>
<td>316LSS</td>
<td>SBS</td>
<td>BSC</td>
<td>Approved</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cypher®</td>
<td>Sirolimus</td>
<td>BxVelocity</td>
<td>140</td>
<td>316LSS</td>
<td>PEVA/PMBA</td>
<td>Cordis, J&amp;J</td>
<td>Approved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second</td>
<td>Endeavour®</td>
<td>Zotarolimus</td>
<td>Driver</td>
<td>91</td>
<td>Cobalt</td>
<td>PC</td>
<td>Medtronic</td>
<td>Approved</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xience®</td>
<td>Eversolimus</td>
<td>ML-VISION®</td>
<td>81</td>
<td>Cobalt</td>
<td>Fluropolym</td>
<td>Abbott</td>
<td>Approved</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BioMatrix</td>
<td>Biolimus A9</td>
<td>S stent</td>
<td>N/A</td>
<td>316LSS</td>
<td>PLA</td>
<td>Biosensor Int</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nobori</td>
<td>Biolimus A9</td>
<td>Nobori Stent</td>
<td>112</td>
<td>316LSS</td>
<td>PLA</td>
<td>TERUMO</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xxent</td>
<td>Biolimus A9</td>
<td>NA® DES</td>
<td>Cobalt-adjustable length</td>
<td>PLA</td>
<td>PLA</td>
<td>Xxent</td>
<td>inv</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New</td>
<td>BioFreedom</td>
<td>Biolimus A9</td>
<td>112</td>
<td>316LSS</td>
<td>No polymer-Texture</td>
<td>Biosensor Int</td>
<td>inv</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generation</td>
<td>Janus</td>
<td>Tacrolimus</td>
<td>110</td>
<td>316LSS</td>
<td>No polymer-Reservoir</td>
<td>Sorin</td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and Pipeline</td>
<td>Yukon</td>
<td>Sirolimus</td>
<td>87</td>
<td>316LSS</td>
<td>No polymer-microporous</td>
<td>Yukon</td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genous</td>
<td>Anti-CD 34 antibody</td>
<td>100</td>
<td>316LSS</td>
<td>No Polymer</td>
<td>OrbusNeich</td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>JACTax Stent</td>
<td>Paclitaxel</td>
<td>316L</td>
<td>PLA with microdroplet</td>
<td>Labcoat</td>
<td>inv</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MIV</td>
<td>Sirolimus</td>
<td>87</td>
<td>Cobalt</td>
<td>Hap</td>
<td>MIV therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. The current commercially available and investigational DESs and their status

### 3.1 Cypher® stent

Cypher® stent has 8-33 mm in length and is offered in 2.5-3.5 mm diameters. Its coating matrix is composed of three nonbiodegradable polymers: Parylene C coated primer layer for improving adhesion of polymer to the metal surface, followed by a layer of polyethylene-co-vinyl acetate (PEVA)/poly n-butyl methacrylate (PMBA) copolymer containing the active agent of Sirolimus. The top layer is a drug-free coating of PBMA to control drug release and to prevent a burst effect. The Cypher® stent releases 50% of its Sirolimus content during the first week after implantation and 85% of the drug over 30 days. All of the Sirolimus is eluted over 90 days.

### 3.2 Taxus® stent

Taxus® stent comes in lengths of 8-28 mm and diameters of 2.5-3.75 mm. The stent is coated with non-biodegradable poly(styrene-b-isobutylene-b-styrene), known as TransLute polymer. The stent provides a burst release of Paclitaxel during the initial 48 hours followed by slow release over the next 10 days and no further release after 30 days.

### 3.3 Endeavour® DES

Endeavour® stent is a cobalt chrome stent with strut thickness of 91 µm (originally S660 stent). The stent was coated with 4.3 µm of phosphorylcholine polymer and the immunosuppressive drug: Zotarolimus an analog of Sirolimus.
3.4 Xience® DES

Xience® stent is the most recently FDA approved DES. The stent is made by using Abbott’s cobalt chrome Multilink® Vision stent as a platform, coated with 7.6um of nonbiodegradable fluropolymer and another Sirolimus analogue drug, Everolimus.

4. Fully Biodegradable Drug Eluting Stent (BDES)

Despite a tremendous amount of capital invested in developing fully biodegradable stents to overcome the drawbacks existing in current nonbiodegradable stents, only five fully biodegradable stents have been investigated in humans so far:

1. The Igaki-Tamai bioabsorbable stent (Igaki Medical Planning Company, Kyoto, Japan)
2. Biodegradable everolimus eluting XIENCE V stent (BVS, Abbott Vascular, Santa Clara, CA, USA).
3. Tyrosine polycarbonate biodegradable stent (Reva Medical Inc, San Diego, CA)
4. Salicylate-based polyanhydride ester biodegradable sirolimus-eluting stent (Ideal™ Bioabsorbable Therapeutics Inc., CA, USA), and
5. Biodegradable magnesium alloy stent (Biotronik AG, Berlin, German)

Table 2 below summarizes the physical, chemical and structural characteristics of these five stents (159).

4.1 The Igaki-Tamai Bioabsorbable Stent

Igaki-Tamai Bioabsorbable Stent is the first absorbable stent that was implanted in humans. It is constructed from poly-L-lactic acid (PLLA). The stent is designed in a zig-zag helical coil structure with a 170um strut thickness. The stent is delivered by a balloon-mounted self-expanding sheathed system with warmed contrast medium. As PLLA is radiolucent, gold markers at each end provide radio-opacity for stent identification. The stent does not release any antiproliferative drug. In the preliminary, first-in-man prospective, nonrandomized clinical trial that enrolled 50 patients, a 4-year follow-up of all the patients (100%) revealed a low complication rate with 1 in-hospital stent thrombosis causing a Q-wave MI, 1 non cardiac death, and 18% repeat PCI and no surgical revascularization. Although there have been no further human coronary implants and the focus is now on a peripheral application, this stent is important in the history of PCI with absorbable stents.

4.2 Biodegradable everolimus-eluting XIENCE V stent

XIENCE Stent has a backbone of circumferential hoops of crystalline PLA, with a strut thickness of 150μm, linked directly together or held by straight bridges achieving a radial strength similar to the Multi-link Vision metal stent. At both ends of the stent, two adjacent radio-opaque metal markers facilitate correct fluoroscopic positioning. The stent was coated with everolimus (8.2 μg/mm) and amorphous PLA matrix in the ratio of 1:1. Eighty percent of the coated drug is released in 30 days, which is similar to the release patterns of the Xience V™ and Cypher® DESs. The stent has been evaluated in an observational first-in-man study of 30 patients with single de novo coronary artery lesions. At the 2-year follow-up, the device has been shown to be safe with no cardiac deaths, target lesion revascularizations, nor stent thromboses and only one non-Q wave MI. In-stent late loss amounted to 0.43 ± 0.44 mm at 6 months and 0.48 ± 0.28 mm at 2 years. Binary restenosis
was observed in 7.7% of patients (2/26) at 6 months and in 0% of patients at 2 years (0/19). One third of stent struts had resolved after 2 years as assessed by optical coherence tomography. Although these data are encouraging, the small number of patients enrolled in the trial and the simplicity of the lesions treated means that a great deal of work remains to be done before the device can be considered for routine use in clinical practice. The stent is currently commercially available in Europe.

4.3 Tyrosine polycarbonate biodegradable REVA stent

The REVA stent is made from monomeric units of the common amino acid L-tyrosine, chemically modified to incorporate iodine molecules so as to make this stent radiopaque. This polymer degrades to carbon dioxide and water in a similar fashion to PLA. The stent struts were designed with a “slide and lock” feature that enables strut thickness to be reduced without compromising radial integrity. The RESORB first-in-man trial showed unfavorable outcomes between 4 and 6 months post-implantation with a higher-than-anticipated target lesion revascularization rate driven mainly by reduced stent diameter.

4.4 Polyanhydride ester (PAE) polymeric stent

The PAE stent is made by incorporating salicylic acid into the backbone of a PAE polymer. The stent surface is coated with Sirolimus with complete elution of the drug by 30 days. The stent offers the advantages of being absorbable and providing anti-inflammatory and antiproliferative properties. In the first-in-man Whisper trial, a stent with strut thickness of 200um and a crossing profile of 2.0 mm with a stent-to-artery coverage of 65% was implanted in 8 patients. Because of the higher-than-expected intimal hyperplasia in this FIM study, a subsequent design with thinner struts, a higher dose of Sirolimus, and a lower percent wall coverage is currently under investigation.

4.5 Absorbable magnesium stent

The AMS stent is composed of 93% magnesium and 7% rare-earth metals. It degrades within the body over a 2-to-3-month time frame, forming inorganic salts containing calcium, chloride, oxide, sulfates and phosphates. The AMS stent has been evaluated in an observational study (PROGRESS) of 71 patients with an angiographic and IVUS assessment at 4 months and clinical follow-up at 1 year. The relatively high in-stent late loss of 1.08 ± 0.49 mm at 4 months translated into a TLR rate of 48.4% at 1 year. The main contributors to restenosis, as detected by IVUS at 4 months, were a decrease of external elastic membrane volume and neointimal hyperplasia, but only small remnants of the stent material were observed at 4 months.

5. Future Development of DES

Ideal DES, from a clinical aspect, should possess the following characteristics: a remarkable ease of use, unparalleled efficacy, impeccable safety, and restoration of conduit vessel physiology. However, from an engineering point of view, it is impossible to incorporate all parameters to make an “apple-pie” DES. Therefore the next generation of DES will be continuously developed by optimizing these three components through a variety ways including the new material selection, new platform design, and new drug incorporation, etc.
<table>
<thead>
<tr>
<th>Stents</th>
<th>Strut Material</th>
<th>Coating Material</th>
<th>Design</th>
<th>Absorption Products</th>
<th>Drug Elution</th>
<th>Stent Radiopacity</th>
<th>Depolyment</th>
<th>Strut Thickness (um)</th>
<th>Crossing Profile (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Igaki-Tamai PLLA</td>
<td>Nil</td>
<td>Zig-Zag helical coils with straight bridge</td>
<td>Lactic acid, CO₂, and H₂O</td>
<td>Nil</td>
<td>Gold marker</td>
<td>Self expanding &amp; heated balloon</td>
<td>170</td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Bioabsorable Magnesium Alloy</td>
<td>Metal Magnesium Alloy</td>
<td>Nil</td>
<td>Sinusoidal in-phase hoop linked by straight bridge</td>
<td>Not applicable</td>
<td>Nil</td>
<td>Nil</td>
<td>Balloon</td>
<td>165</td>
<td>1.2</td>
</tr>
<tr>
<td>BVS 1.0 PLLA PDLA</td>
<td>PDLA</td>
<td>In-phase hoop with straight &amp; direct link</td>
<td>Lactic acid, CO₂ and H₂O</td>
<td>Everolimus</td>
<td>Platinum marker</td>
<td>Balloon</td>
<td>156</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>BVS 1.1 PLLA PDLA</td>
<td>PDLA</td>
<td>Out-of-phase hoop with straight &amp; direct link</td>
<td>Lactic acid, CO₂ and H₂O</td>
<td>Everolimus</td>
<td>Platinum marker</td>
<td>Balloon</td>
<td>156</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>REVA Tyrosine-Derived Polycarbonate</td>
<td>Nil</td>
<td>Side and lock</td>
<td>Amino acids, ethanol and CO₂</td>
<td>Nil</td>
<td>Idodine impregnated</td>
<td>Balloon</td>
<td>200</td>
<td>1.7</td>
<td></td>
</tr>
<tr>
<td>BTI Bioabsorable Therapeutics Incorporated</td>
<td>Salicylate linker</td>
<td>Salicylate different linker</td>
<td>Tuber with laser cut void</td>
<td>Salicylate, CO₂, and H₂O</td>
<td>Sirolimus &amp; Salicylate</td>
<td>Nil</td>
<td>Balloon</td>
<td>200</td>
<td></td>
</tr>
</tbody>
</table>
The challenges faced by emerging technologies are to reduce restenosis in high-risk lesions, without compromising healing, in order to avoid late thrombotic complications and to improve system deliverability to allow treatment of more complex patients. Currently, a number of strategies are being utilized to achieve these goals through the development of novel stent platforms, coating with biodegradable polymers or moving away from polymers, and with new generations and/or combinations of biological agents that both inhibit proliferation and promote endothelialization. With the recent positive data from Abbott’s ABSORB trial, clinical consensus is building that fully bioabsorbable stents (BDS) represent the next generation in DES. Table 3 summarizes the potential benefits for the biodegradable DES.

<table>
<thead>
<tr>
<th>Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>May limit late-stent thrombosis</td>
</tr>
<tr>
<td>Allows late favorable positive remodeling</td>
</tr>
<tr>
<td>May reduce long-term dual antiplatelet therapy</td>
</tr>
<tr>
<td>Has Larger drug-loading capacity</td>
</tr>
<tr>
<td>Addresses patient's concerns about permanent implants</td>
</tr>
<tr>
<td>Facilitates noninvasive diagnosis imaging (MR/CT)</td>
</tr>
<tr>
<td>Surgical option not restricted</td>
</tr>
<tr>
<td>Easier repeat revascularization</td>
</tr>
</tbody>
</table>

Table 3. Potential Benefits of Biodegradable Stent.

6. References


Coronary Arterial Drug-Eluting Stent: From Structure to Clinical


[95] Slottow TLP, Steinberg DH, Waksman R. Overview of the 2007 food and drug administration circulatory system devices panel meeting on patent foramen ovale closure devices. Circulation. 2007;116:677-682


This book has “wide geography” both literally and figuratively. First of all, this book brings together contributions from around the world, both from post-industrial countries and developing world. This is natural, because coronary artery disease is becoming pandemic worldwide. CAD is the single most frequent cause of death in developed countries, causes about 1 in every 5 deaths. Mortality from cardiovascular disease is predicted to reach 23.4 million in 2030. Moreover, in the developing world, cardiovascular disease tends to affect people at a younger age and thus could negatively affect the workforce and economic productivity. The morbidity, mortality, and socioeconomic importance of CAD make its diagnosis and management fundamental for all practicing physicians. On another hand, the book widely represents “geography” of CAD itself, i.e. many various aspects of its pathophysiology, epidemiology, diagnosis, treatment are touched in this book. This book does not pretend on complete and integral description of the Coronary artery disease. Rather, it contains selected issues on this complex multifactorial disease. Nevertheless, we hope that readers will find Coronary Artery Disease useful for clinical practice and further research.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: